Myrzi (Desogestrel, Ethinylestradiol)

Myrzi is a combined hormonal contraceptive used within the family‑planning and reproductive‑health pathway.

• Prevention of pregnancy: provides effective, reversible contraception for women of child‑bearing potential.
• Family planning: enables reliable birth control as part of a planned pregnancy strategy.
• Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns.

• Desogestrel and ethinylestradiol act together to suppress the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), thereby inhibiting ovulation. The estrogen component stabilises the endometrium, while the progestogen component thickens cervical mucus, creating a hostile environment for sperm and reducing the chance of fertilisation and implantation.

Myrzi may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild stomach upset, often resolves with continued use.
• Headache: tension‑type or migraine‑like pain.
• Breast tenderness: temporary swelling or discomfort.
• Spotting or breakthrough bleeding: irregular bleeding between periods.
• Weight gain: modest increase in body weight.
• Mood changes: irritability or mild depressive symptoms.

Serious or Rare Side Effects

• Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
• Arterial thrombosis: stroke or myocardial infarction.
• Hypertension: new‑onset or worsening high blood pressure.
• Liver disorders: cholestatic jaundice or hepatic adenoma.
• Gallbladder disease: gallstones or cholecystitis.
• Severe allergic reaction: rash, swelling, or anaphylaxis.

Before starting Myrzi, consider the following safety measures.

• Smoking: avoid if over 35 years old, as risk of cardiovascular events rises.
• Cardiovascular disease: assess history of heart attack, stroke, or clotting disorders.
• Liver function: evaluate for active liver disease or severe impairment.
• Migraine with aura: contraindicated due to increased stroke risk.
• Pregnancy testing: ensure the patient is not pregnant before initiation.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Myrzi can interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid)

• Antiepileptic drugs (e.g., carbamazepine, phenytoin): markedly reduce contraceptive efficacy.
• Rifampicin and other strong enzyme inducers: may lead to contraceptive failure.
• Certain HIV protease inhibitors (e.g., ritonavir): increase risk of thrombotic events.

Moderate Interactions (Monitor Closely)

• Antifungal agents (e.g., fluconazole): may increase hormone levels, watch for side‑effects.
• Antibiotics (e.g., tetracycline): occasional reduction in contraceptive effect, advise backup method.
• St. John’s wort: may lower hormone concentrations, consider alternative contraception.